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A B S T R A C T
Nitro-fatty acids (NO2-FA) are electrophilic lipid mediators derived from unsaturated fatty acid nitration. These
species are produced endogenously by metabolic and inflammatory reactions and mediate anti-oxidative and
anti-inflammatory responses. NO2-FA have been postulated as partial agonists of the Peroxisome Proliferator-
Activated Receptor gamma (PPARγ), which is predominantly expressed in adipocytes and myeloid cells. Herein,
we explored molecular and cellular events associated with PPARγ activation by NO2-FA in monocytes and
macrophages. NO2-FA induced the expression of two PPARγ reporter genes, Fatty Acid Binding Protein 4
(FABP4) and the scavenger receptor CD36, at early stages of monocyte differentiation into macrophages. These
responses were inhibited by the specific PPARγ inhibitor GW9662. Attenuated NO2-FA effects on PPARγ sig-
naling were observed once cells were differentiated into macrophages, with a significant but lower FABP4 up-
regulation, and no induction of CD36. Using in vitro and in silico approaches, we demonstrated that NO2-FA bind
to FABP4. Furthermore, the inhibition of monocyte FA binding by FABP4 diminished NO2-FA-induced upre-
gulation of reporter genes that are transcriptionally regulated by PPARγ, Keap1/Nrf2 and HSF1, indicating that
FABP4 inhibition mitigates NO2-FA signaling actions. Overall, our results affirm that NO2-FA activate PPARγ in
monocytes and upregulate FABP4 expression, thus promoting a positive amplification loop for the downstream
signaling actions of this mediator.
1. Introduction
Nitrated derivatives of unsaturated fatty acids (NO2-FA) mediate
pleiotropic cell signaling actions [1,2]. NO2-FA are endogenously gen-
erated upon nitrogen dioxide (·NO2) addition to double bonds [3].
Among unsaturated fatty acids, those containing conjugated diene
moieties are preferential substrates for nitration, because of the greater
reactivity of the external flanking carbons of the conjugated diene
moiety [4]. Conjugated linoleic acid (CLA), the most abundant dietary
conjugated fatty acid, has been identified as a major endogenous sub-
strate for nitration, generating nitro conjugated linoleic acid (NO2-CLA)
[5]. In healthy humans, CLA nitration occurs during digestion of lipid-
containing foods, leading to nanomolar concentrations of unesterified
NO2-CLA in plasma [6]. Current data indicate that NO2-CLA levels rise
in metabolically-stressed and/or inflamed tissues because of down-
stream nitro-oxidative reactions stemming from nitric oxide synthase
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induction in inflammatory cells and tissues [2,7,8]. Despite the much
lower reactivity of monounsaturated fatty acids, low levels of nitrated
oleic acid have been reported in human plasma [9].
NO2-FA modulate cell metabolic and inflammatory responses
[5,10–17] by multiple mechanisms, predominantly those involving
post-translational modifications (PTM) of target proteins that regulate
intracellular signaling responses and gene expression. These PTMs are a
consequence of the soft electrophilic nature of NO2-FA, which promotes
reversible Michael addition reactions with soft nucleophilic groups such
as His or Cys in proteins, leading to alterations in protein cell dis-
tribution and/or function [18]. The nuclear receptor PPARγ (Peroxi-
some Proliferator-Activated Receptor γ) is one target of NO2-FA. PPARγ is
a multi-domain protein with high affinity for lipophilic ligands. Ago-
nists stabilize the active state of PPARγ, regulating the expression of
genes involved in lipid metabolism or inflammation [19,20]. NO2-FA
bind to the PPARγ ligand-binding domain (LBD) and covalently react
with a redox-sensitive Cys-285 in the LBD, partially activating the
transcriptional function of the receptor [21–25]. This contrasts with the
PPARγ activation profile induced by stronger ligands or full agonists
such as the family of synthetic thiazolidinedione activators [26]. Be-
sides PPARγ, Keap1 (Kelch-like ECH-associated protein 1) was described
as a NO2-FA target with implications for cytoprotective responses
[27–30]. NO2-FA react with key cysteine residues in Keap1, resulting in
reduced proteasomal degradation of the transcription factor Nrf2 (Nu-
clear factor-erythroid 2-related factor 2), and activation of Nrf2-depen-
dent transcription of anti-oxidant and detoxifying genes, such as heme
oxygenase-1 (HMOX1) and glutamate cysteine ligase modulatory gene
(GCLM). Finally, NO2-FA adduction to members of the heat shock
protein family (HSP) that sense electrophiles, leads to activation of
HSF1-regulated gene expression [30] and downstream anti-in-
flammatory effects in myeloid cells [31,32]. This NO2-FA signaling
mechanism in endothelial cells stimulates HSPA1A expression [28].
Beyond the pleiotropic nature of NO2-FA, their protein targets will
depend on several factors including cell redox and activation status as
well as the intracellular half-life and stability of NO2-FA.
The effect of NO2-FA on PPARγ activation has primarily been stu-
died in a metabolic context using fibroblasts, adipocytes, mammary
epithelial (MCF7), or kidney cell lines (CV-1) [33–35]. Reporter assays
have also been used but do not reliably reproduce physiological PPARγ
expression levels and interactions with co-regulators (co-activators and
co-repressors) that modulate its transcriptional activity [21–23]. In
aggregate, NO2-FA activation of PPARγ and subsequent modulation of
cell functions is still poorly understood, particularly in the context of
immunological responses. Monocytes and macrophages are innate cell
populations of foremost importance in mediating integrated in-
flammatory responses, eliminating pathogens and contributing to tissue
homeostasis. The recruitment of monocytes and their subsequent dif-
ferentiation into macrophages gains relevance during inflammation to
reinforce the immune response. Previously, PPARγ-independent effects
on monocyte and macrophage inflammatory responses to NO2-FA have
been reported [10,36]. In this work, we examined NO2-FA activation of
PPARγ in both human monocytes undergoing differentiation into
macrophages (termed differentiating monocytes) and macrophages.
We report herein that low μM levels of NO2-FA activated PPARγ in
differentiating monocytes and to a lesser extent in already-differ-
entiated macrophages. The most robust PPARγ-regulated gene expres-
sion response in these cells was the upregulation of FABP4, a member of
the fatty acid-binding protein family (FABP) that transports fatty acids
between cell compartments [37]. NO2-FA have limited solubility in
aqueous milieu, thus this FABP4 upregulation and transport capability
induced a significant impact on NO2-FA trafficking to nuclear and cy-
toplasmic targets including PPARγ, in turn regulating downstream cell
signaling responses. These responses were abrogated by FABP4 in-
hibitors in differentiating monocytes, affirming that FABP4 plays a
crucial role in the transduction of NO2-FA by (at least) PPARγ, Keap1/
Nrf2 and HSP-regulated signaling networks.
2. Materials and methods
2.1. Chemical reagents
Reagents of analytical grade were purchased from Sigma (St. Louis,
MO, USA) unless otherwise stated. Octadec-9-enoic acid (oleic acid,
OA), octadec-9,11-dienoic acid (conjugated linoleic acid, CLA) and
5,8,11,14-eicosatetraenoic acid (arachidonic acid, AA) were obtained
from Nu-Check Prep, Inc (Elysian, MN, USA). 9- and 12-nitro-octadec-
9,11-dienoic acid (9-NO2-CLA and 12-NO2-CLA), 9- and 10-nitro-oc-
tadec-9-enoic acid (9-NO2-OA and 10-NO2-OA) and 10-nitro-octadeca-
noic acid (NO2-SA) were synthesized as described previously [5,38,39].
The terms NO2-CLA and nitro oleic acid (NO2-OA) refer to the mixture
of the corresponding above-mentioned positional isomers. AA nitration
was carried out as previously described [11] to obtain a mixture of
positional isomers referred to as nitroarachidonic acid (NO2-AA). Ro-
siglitazone (Rosi), GW9662, and HTS01037 (HTS) were obtained from
Cayman Chem (USA) while BMS 309403 (BMS) was acquired from
ApexBio (USA).
2.2. Recombinant mouse FABP4 and rabbit anti-mouse FABP4 polyclonal
antibodies
Recombinant mouse FABP4 (rFABP4) was expressed and
purified following conventional protocols as previously described
(Supplementary Fig. 1) [40]. Polyclonal antiserum against rFABP4 was
raised in rabbits following standard protocols. All procedures were
carried out in accordance with the ethical guidelines of the Honorary
Commission of Animal Experimentation (CHEA) from UdelaR. Briefly, a
New Zealand rabbit was injected subcutaneously with 500 μg of pur-
ified rFABP4 in an emulsion made of water in oil, prepared with In-
complete Freund Adjuvant. A second dose (booster) was similarly
performed when the serum antibody titer anti-rFABP4 significantly
dropped (about 16-times lower than the maximum reached). Bleeding
was done at day 47 post-booster. The polyclonal antisera obtained
showed a titer of 1/48.000 by ELISA and showed to recognize by
Western blot a 14 kDa band present in a THP-1 cell extract, which was
compatible with FABP4. The fraction of polyclonal anti-rFABP4 anti-
bodies was purified by immunoaffinity using rFABP4 conjugated to
NHS-Sepharose and 0.1 M glycine pH 2.0 for elution. In parallel, we
obtained the polyclonal antisera fraction non-specifically bound to Se-
pharose as a control.
2.3. Cell culture for NO2-FA stimulation
Human pre-monocytic THP-1 cells (ATCC, USA), a suitable model of
primary human monocytes and macrophages [41], was used. Cells were
cultured in RPMI medium (RPMI 1640 supplemented with 10 mM
HEPES, 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 2 mM
glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 250 ng/
mL amphotericin B) plus 10% fetal bovine serum (FBS, GIBCO). Cells
were maintained at 37 °C in a humidified atmosphere of 5% CO2 in air,
and subcultured every 3–4 days to maintain cell density between 0.2
and 1.0 × 106 cells/mL. Cells were plated at 5 × 105 cells/well in RPMI
medium supplemented with 5% FBS and macrophage differentiation
was induced with 50 ng/mL phorbol esters (PMA, SIGMA). NO2-FA,
their corresponding fatty acid precursors (FA) and Rosi (a well-known
PPARγ ligand) were tested at a final concentration of 1 μM, and the
vehicle (DMSO) was used as a negative control. For assessing effects on
differentiating monocytes, tested compounds were added together with
PMA. For assessing effects on completely differentiated macrophages,
macrophages were obtained after 72 h differentiation with PMA, cul-
tured in RPMI medium without PMA for 48 h, and subsequently sti-
mulated with NO2-FA, Rosi or controls. In all assays, stimulation was
stopped after 6 h or 16 h stimulation for mRNA levels and protein
synthesis analysis, respectively. In order to evaluate the contribution of
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PPARγ activation to NO2-FA-induced effects, similar experiments were
done in the presence of a PPARγ inhibitor, GW9662. Briefly, cells were
treated with PMA for 3.5 h, and then for 30 min with GW9662 (1 or
2.5 μM). Cells were then stimulated with NO2-FA or controls and mRNA
and protein levels examined at 6 h or 16 h post-stimulation, respec-
tively. The role of FABP4 on NO2-FA cell signaling actions was eval-
uated using the FABP4 inhibitors BMS [42] and HTS [43] in the pre-
sence of 5% delipidated FBS (PAN Biotech, Germany). Cells were
pretreated with PMA together with BMS (25 μM) or HTS (15 μM) for 2 h
and then stimulated with NO2-FA or controls for 6 h mRNA expression
was then examined as described below. In the case of HTS, an addi-
tional pre-incubation (24 h) was carried as previously described [44].
2.4. Cell viability
Cell viability was analyzed using the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Briefly, cells were
cultured in the presence 200 μg/ml of MTT in PBS with 0.1% glucose
for 3 h at 37 °C, 5% CO2. Afterward, cells were washed with PBS, for-
mazan was dissolved in DMSO and the absorbance at 560 nm was
measured. In the case of differentiating monocytes, it was also analyzed
on the basis of exclusion of the fixable viability dye (LIVE/DEAD,
Invitrogen) and measured by flow cytometry.
2.5. Gene expression analysis
After stimulation, total cellular mRNA was isolated from cells using
the TRIzol Reagent (Ambion, Life Technologies, USA) accordingly to
the manufacturer's recommendations. Traces of DNA were removed by
treatment with DNAse-I following the manufacturer's instructions
(Fermentas, Thermo Fisher Scientific, USA). The synthesis of the first
strand complementary DNA (cDNA) was carried out using 1 μg of total
mRNA, M-MLV reverse transcriptase (200 Units, Life Technologies,
USA), 0,5 mM dNTPs, 5 μM random primers, Ribolock (40 Units,
Fermentas) at 25 °C for 10 min, followed by 37 °C for 50 min and 70 °C
for 15 min. Template DNA was amplified by quantitative real-time PCR
using Quantitect SYBR Green PCR kit (Qiagen, Hilden-Germany) in a
Rotor-Gene Q real-time PCR cycler (Qiagen), according to the following
protocol: 15 min at 95 °C, followed by 40 cycles at 94 °C for 15 s, at
50 °C for 30 s and at 72 °C for 30 s.
The primers, designed using Primer Express software (Applied
Biosystems, USA), are listed in Table 1 and were used at a final con-
centration of 0.9 μM. The expression of genes of interest was normalized
using GAPDH as housekeeping gene, except for assays using BMS where
18S was used. The relative mRNA amount in each sample was estimated
using the 2−ΔΔCt method [45], where ΔCt = Ct gene of interest-Ct
housekeeping, and expressed as relative mRNA levels in the test group
compared to the control group.
2.6. FABP4 detection by immunofluorescence
THP-1 cells (5 × 105 cells) were seeded on coverslips and stimulated
with PMA (50 ng/mL) plus 1 μM concentration of NO2-FA, FA, Rosi or
DMSO (vehicle) in RPMI supplemented with 5% fetal delipidated FBS,
for 10 h at 37 °C and in a humidified atmosphere of 5% CO2. Cells were
subsequently fixed with 4% paraformaldehyde in PBS, and coverslips
were incubated overnight at 4 °C with the affinity-purified rabbit anti-
rFABP4 antibody (1:100) or the corresponding control antibody. After
washing 3 times with PBS, cells were stained using goat anti-rabbit IgG
(H+L) conjugated with Alexa Fluor TM 488 (1:1600, Invitrogen) for
1.5 h, and then with DAPI (300 μM, Calbiochem-Novabiochem, USA)
for 30 min. Cells were observed under epifluorescence microscopy
(Nikon E800, Japan). To measure FABP4 nuclear translocation, cells
were similarly stimulated for 10 h with PMA plus 1 μM NO2-FA in order
to reach detectable FABP4 levels, Leptomycin B (10 ng/ml) was added
for 30 min and a short re-stimulation (30 or 60 min) with NO2-FA, FA or
Rosi (between 1 and 10 μM) was performed. Cells were stained as de-
scribed above, but also using DAPI and rhodamine-phalloidin (0.3 μg/
ml, Santa Cruz Biotechnology, USA) for nuclear and actin staining,
respectively. Images were obtained with an LSM 800-AiryScan confocal
microscope (Zeiss, Germany) and processed using FIJI/ImageJ [46].
Quantification was performed using at least 30 cells per condition in
three independent experiments. The nucleus and the whole cell were
delimitated according to DAPI and rhodamine staining, respectively,
and integrated density (selected area*mean grey value, ID) was mea-
sured for each cell compartment. FABP4 distribution was analyzed by
determining the nuclear/cytoplasm ratio, calculated as the Nuclear ID/
(Total ID – Nuclear ID) (N/T-N).
2.7. FABP4 detection in cell extracts by Western blot
THP-1 cell extracts were obtained after 16 h of NO2-FA stimulation.
Briefly, monocytes were washed two times with RPMI without FBS at
37 °C, lysed using hypotonic buffer (Hepes 10 mM, EDTA 0.5 mM, KCl
10 mM, DTT 1 mM and protease inhibitor cocktail SIGMA, pH 7.5) and
sonicated (three rounds of 1 min pulses at 15% and 30% of total po-
tency) using an Omni-Ruptor 4000 (OMNI International Inc.). Samples
were analyzed by SDS-PAGE at reducing conditions using poly-
acrylamide 12.5% gels and following conventional protocols. The
proteins were transferred to a PVDF membrane (Millipore) and, after
blocking with PBS 0.5% bovine serum albumin (BSA), probed with
rabbit anti-rFABP4 antisera (1:20000 in PBS containing 0.05% BSA and
0.05% Tween 20) or rabbit anti-human tubulin IgG (1:1000, Cell
Signaling, USA) followed by peroxidase-conjugated anti-rabbit IgG
(1:2000, Calbiochem). Detection was carried out using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Fischer Scientific) in
an imaging system (G:BOX, Syngene, India).
Table 1
Primers for real-time PCR.
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2.8. CD36 detection by flow cytometry
Stimulated THP-1 monocytes (1 × 106 cells/well) were washed
twice with cold PBS and detached by treatment with PBS containing
1 mM EDTA, 0.1% NaN3, 0.1% glucose (PBSFC buffer) for 10 min at 4 °C.
After blocking with PBSFC supplemented with 0.1% SFB, cells were
incubated with mouse IgM anti-human CD36 (BD Biosciences, USA) or
with an IgM isotype control (BD Biosciences) following manufacturer's
recommendations. Then, cells were washed 3 times and development
was carried out by incubation with phycoerythrin-conjugated anti-
mouse IgM (BD Biosciences) according to the manufacturer's protocol.
Cells were recorded on a FACSCalibur equipment (BD Biosciences) and
analyzed with FlowJo (version 7.6, USA, www.flowjo.com).
2.9. FABP4 binding assays
The fluorimetric binding assay was performed as previously de-
scribed [47]. rFABP4 (3 μM) was incubated with the hydrophobic
fluorescence probe 8-anilinonaphthalene-1-sulfonic acid (ANS, 10 μM,
Molecular Probes) for 5 min in 1 mL final volume of phosphate buffer
(5 mM K2HPO4, 5 mM KH2PO4, 150 mM KCl, pH 7,4). Using a Fluor-
olog-3 (Horiba-Yvon) spectrofluorometer, the probe was excited at
400 nm (excitation slit 1), and emission spectra was registered between
420 and 600 nm (emission slit 2) at 25 °C, using FluorEssence™ soft-
ware. Then, small amounts of the NO2-FA were added progressively and
the emission spectrum was registered 2 min after each addition to reach
FABP4 saturation. NO2-CLA, NO2-OA, and NO2-AA were tested and
compared with their FA precursors (CLA, OA and AA, respectively).
Each experiment was done at least in triplicates. Fluorescence data
were fitted to a hyperbolic decay using SigmaPlot (version 11.0, Systat
Software, Inc., USA, www.systatsoftware.com). The apparent dissocia-
tion constant (Kdapp) was calculated using the equation EC50ligand/
[ANS] = Kd,ligand/Kd,ANS as previously described [48]. To obtain Kd,ANS,
FABP4 (2 μM) was titrated with the fluorescent probe until reaching
saturation. Curves were fitted using SigmaPlot to a one-site ligand
binding saturation model, and Kd,ANS was calculated as the mean of four
independent experiments.
2.10. In silico prediction and analysis of FA and NO2-FA binding to murine
FABP4 in 1:1 complexes
The crystallographic structure of the available murine
mFABP4:oleate complex in the open portal (inactive for translocation)
conformation (PDB 1LID) [49] was taken as starting point for con-
structing the corresponding mFABP4:FA or mFABP4:NO2-FA 1:1 com-
plexes in solution and running 1.2 μs molecular dynamics (MD) NPT
simulations at 310 K and 1 atm using the AMBER 16 suite [50] (see
details on the simulations and trajectory analysis in the supplementary
information). The study included OA and conjugated CLA, and the
corresponding regioisomeric nitroalkene derivatives (9-/10-NO2-OA
and 9-/12-NO2-CLA) as ligands, whose anionic structure in solution was
determined by Density Functional Theory (DFT) quantum mechanics
(QM) calculations [51] in a IEF-PCM continuous solvent [52] using
Gaussian09 [53] (details on QM modeling in the supplementary in-
formation). Representative structures for each of the six complexes
under study were obtained from MD by hierarchical-agglomerative
clustering analysis and the presence of active/inactive for translocation
conformations was monitored inspecting the distance between Phe57
(βC-βD loop) and Thr29 (αII helix) along the trajectories with cpptraj,
taking values smaller than 8.5 Å as indicative of a closed conformation.
In order to analyze the trends on binding affinity along the series of FA/
NO2-FA looking for evidence on eventual regioisomeric modulation,
MM/PB(GB)SA binding free energies [54] were also obtained within a
single-trajectory approach, extracting 201 snapshots from the 1.2 μs
MD simulations separated every 500 ns (the first 200 ns were discarded)
with the mmpbsa.py module [55] of AmberTools17 [50].
2.11. Data analysis
All experiments were performed at least three independent times
(n = 3) in duplicate. Statistical analysis was carried out with GraphPad
Prism (version 5, GraphPad Software, USA, www.graphpad.com) using
two-way analysis of variance (ANOVA) for multiple comparisons, with
Tukey post-test, or one-way ANOVA with Dunn post-test as indicated.
For immunofluorescence studies, when comparing two groups, an un-
paired t-test was used. Differences were considered significant when
p≤ 0.05.
3. Results
3.1. NO2-FA activate PPARγ in differentiating monocytes and to a lesser
extent in macrophages
For studying the ability of NO2-FA to activate PPARγ in differ-
entiating monocytes and macrophages, cell response to the full PPARγ
agonist Rosiglitazone (Rosi) was firstly examined by quantitative ana-
lysis of mRNA expression of a series of potential PPARγ reporter genes
(Supplementary Fig. 2). FABP4 was the most upregulated gene in both
cell types, exhibiting the highest increment at 6 h post-stimulation
(about 20-fold and 3-fold, Supplementary Figs. 2e and 2f, respectively).
FABP5 and CD36 expression were moderately upregulated by Rosi in
differentiating monocytes and macrophages, with increases slightly
higher in monocytes than macrophages. Regarding ABCA1, ABCG1, and
CPT1A, Rosi induced dissimilar and modest responses in monocytes and
macrophages. Based on these results, FABP4, FABP5, and CD36 were
chosen as target genes for studying the effect of NO2-FA on PPARγ
activation.
Studies were carried out using low micromolar concentrations of
NO2-OA, NO2-CLA, and NO2-AA (up to 1 μM), which are likely close to
physiological levels in an inflammatory milieu [17] and did not cause
alterations in cell viability (Supplementary Fig. 3). We found that all
NO2-FA, but not their corresponding FA precursors, were able to induce
statistically significant increases in FABP4 mRNA levels in differ-
entiating monocytes (Fig. 1a), showing the relevance of nitration for
PPARγ activation. In contrast, FABP5 mRNA levels were unchanged
after NO2-FA stimulation (Fig. 1b) and only NO2-CLA caused a modest
increment in CD36 mRNA levels, suggesting that NO2-CLA was the most
potent PPARγ activator among tested NO2-FA (Fig. 1c). In macro-
phages, NO2-FA stimulation led to increases in FABP4 mRNA levels
(Fig. 1e), but the magnitude of these increases was much lower than
that observed in monocytes (1.6-fold vs. 7.5-fold for NO2-CLA, respec-
tively). Furthermore, no changes in FABP5 and CD36 expression were
observed in macrophages after NO2-FA stimulation while, as expected,
Rosi induced significant rises in these PPARγ target genes (Fig. 1f and
g). Moreover, we measured PPARG mRNA levels in both cell types to
determine whether Rosi and NO2-FA effects could induce an increase in
PPARG expression. Results showed that exposure to Rosi and NO2-FA
did not significantly affect PPARG expression (Fig. 1d and h). In ag-
gregate, these results indicate that NO2-FA could act as partial PPARγ
agonists in human differentiating monocytes and, to a lesser extent, in
human macrophages, enhancing the transcription of genes associated
with lipid metabolism such as CD36 and FABP4.
Next, we analyzed whether upregulation of FABP4 and CD36 tran-
scription by NO2-FA-stimulation led to an increment in protein levels.
To that end, FABP4 levels were determined by immunofluorescence,
using affinity-purified anti-rFABP4 antibodies or its corresponding
control. In agreement with the effects observed at the mRNA level,
stimulation of differentiating monocytes with Rosi or NO2-FA, but not
with native FA, led to significant increases in FABP4 protein expression
(Fig. 2a and b). No reactivity was observed using control antibodies
(Supplementary Fig. 4). FABP5 might cause cross-reactivity in this
assay because of its similar amino acid sequence and 3D-structure to
FABP4 (Supplementary Fig. 5). However, the fluorescence response was
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due to upregulation of FABP4 expression since FABP5 mRNA levels
were unchanged after NO2-FA stimulation of differentiating monocytes
(Fig. 1b). A contrasting scenario was observed in macrophages, in
which NO2-FA treatment did not lead to increases in FABP4 protein
levels (Fig. 2c). Moreover, Rosi was unable to increase FABP4 protein
expression, despite an ability to enhance FABP4 transcription (Fig. 1e),
suggesting that FABP4 synthesis might have reached a plateau under
these conditions. On the other hand, CD36 protein levels were de-
termined by flow cytometry. Among the tested NO2-FA, only NO2-CLA
caused a weak, but statistically significant rise in CD36 protein ex-
pression in differentiating monocytes (Fig. 2d), which correlates with
its ability to upregulate CD36 transcription.
Considering the robustness of NO2-FA transcriptional responses and
their impact on protein expression, studies were then focused on dif-
ferentiating monocytes. The role of PPARγ on NO2-FA induction of
FABP4 and CD36 expression was evaluated using the PPARγ specific
inhibitor GW9662. GW9662 treatment inhibited FABP4 and CD36
mRNA induction triggered by Rosi and NO2-FA in differentiating
Fig. 1. NO2-FA stimulated FABP4 and CD36 mRNA
expression in differentiating monocytes, and to a
lesser extent in macrophages.
Differentiating THP-1 monocytes (a, b, c, d) and
THP-1 macrophages (e, f, g, h), obtained by treat-
ment with PMA, were stimulated with 1 μM con-
centration of Rosi, NO2-FA or their corresponding FA
precursors. In parallel, cells were incubated with
DMSO (vehicle) as a control. After 6 h stimulation,
cells were homogenized to obtain total mRNA, and
FABP4, FABP5, CD36 and PPARγ mRNA levels were
determined by real-time-qPCR and normalized to the
housekeeping gene GAPDH. Results are represented
as relative mRNA levels (fold increase) referred to
Medium group, and correspond to the mean of at
least three independent experiments ± SD. (*)
Indicates statistically significant differences com-
pared with DMSO (Two-way ANOVA, Tukey's
Multiple Comparison test * p˂0.05, **p˂0.01,
***p˂0.001, ****p˂0.0001).
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monocytes (Fig. 3a and b, respectively). Similarly, analysis of FABP4
levels in cell extracts by Western blot (Fig. 3c) showed that GW9662
caused a reduction in FABP4 protein levels induced by Rosi (80% in-
hibition) or NO2-FA (72 to 89% inhibition, Fig. 3d). Altogether, these
results indicate that NO2-FA activated PPARγ in differentiating mono-
cytes. Moreover, NO2-FA effects on FABP4 and CD36 expression were
much lower than those induced by Rosi, supporting the partial PPARγ
agonist actions of nitroalkenes, in agreement with previous studies
using transfected cell lines [25].
3.2. FA nitration did not abrogate FABP4 binding
The induction of FABP4 synthesis by NO2-FA might influence their
own intracellular transport and signaling because FABP4 is the main
FABP isoform involved in intracellular FA transport in monocytes and
macrophages. Nonetheless, the role of NO2-FA binding to FABPs is
unknown, thus we hypothesized that the presence of a nitro group on
the fatty acyl chain might modify FA interactions with FABP4.
Therefore, we studied NO2-FA binding to FABP4 in vitro using a com-
petitive fluorescent binding assay based on the displacement of a
fluorescent hydrophobic probe (ANS), previously bound to FABP4. For
this assay, we used delipidated murine rFABP4 as a model, recognizing
that FABP4 is highly conserved among mammals, with murine and
human FABP4 sharing a high level of primary and secondary structure
identity (both higher than 91%, Supplementary Fig. 6). The addition of
increasing amounts of NO2-FA to rFABP4 bound to ANS (at saturation
conditions induced by a protein to probe molar ratio of 1:3) caused a
progressive decrease in fluorescence, indicating the displacement of
ANS from rFABP4 (Fig. 4). Displacement curves were adjusted to a
hyperbolic decay, suggesting a 1:1 FABP4:NO2-FA stoichiometry ratio
Fig. 2. NO2-FA induced an increase in FABP4 and CD36 protein expression in differentiating monocytes, but not in macrophages.
Differentiating THP-1 monocytes (a, b, d) and THP-1 macrophages (c), obtained by treatment with PMA, were stimulated with 1 μM concentration of Rosi, NO2-FA
or their corresponding FA precursors, or the concentration indicated in the figure. In parallel, cells were incubated with DMSO (vehicle) as a control. After 12 h
stimulation, cells were washed and stained using affinity-purified rabbit anti-rFABP4 antibodies and Alexa488 conjugated anti-rabbit IgG for development. Nuclei
were stained using DAPI. Cells were observed and counted using epifluorescence microscopy. Images were analyzed using Image J software. In (a), panels show
representative images of differentiating monocytes following incubation with the indicated stimuli or control. Graphs in (b) and (c) correspond to the quantification
of FABP4 protein levels in differentiating monocytes and macrophages, respectively. Graphs indicate the Integrated Density (ID, in arbitrary units) for at least 70 cells
per treatment ± SD. (*) and (#) Indicate statistically significant differences compared with DMSO or their non-nitrated precursor, respectively (One-way ANOVA,
Dunn's Multiple Comparison test */#p˂0.05, ***/###p˂0.001). In (d) treatments were carried out for 16 h, then cells were harvested, and CD36 protein levels were
determined by flow cytometry using a mouse IgM anti-human CD36 antibody and a phycoerythrin-conjugated anti-murine IgM for development. Graph represents
protein levels normalized to Medium group, and are the mean of three independent experiments ± SD. (*) Indicates statistically significant differences compared
with DMSO (Two-way ANOVA, Tukey's Multiple Comparison test * p˂0.05, **p˂0.01, ***p˂0.001, ****p˂0.0001).
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in agreement with previous reports [56,57], and allowed Kdapp calcu-
lation. Differences in binding affinity among NO2-FA were noted. NO2-
OA behaved like a high-affinity ligand, whereas NO2-CLA and NO2-AA
acted as weak affinity ligands since they displaced about 84%, 58%,
and 46% of ANS at protein saturation condition, respectively [48]. This
correlated with the fact that NO2-OA showed the lowest Kdapp (Table 2,
indicated with *). On the other hand, according to Kdapp, nitration of
OA, CLA and AA caused a reduction in their rFABP4 affinity (Table 2,
indicated with #), related to variations in binding free-energies of 0.27,
1.376 and 1.47 kcal mol−1 for each mixture of NO2-OA, NO2-CLA and
NO2-AA regioisomers, respectively. Despite such variations, acyl chain
nitration did not abrogate FA binding to FABP4, supporting the idea
that FABP4 could also act as a NO2-FA intracellular carrier.
The in silico results show that FABP4-bound FA/NO2-FA remained
thermodynamically stable throughout the 1.2 μs simulation periods
(Table 2, right) as previously reported for other 1:1 complexes estab-
lished between murine FABP4 and different ligands [49,58–60]. The
corresponding binding free-energies extracted from MM/GB(PB)SA
Fig. 3. Upregulation of FABP4 and CD36 expression by NO2-FA was abolished by a PPARγ specific inhibitor.
Differentiating monocytes were pretreated with the PPARγ specific inhibitor GW9662 (1 μM) for 30 min and afterward, Rosi, NO2-FA and their controls (DMSO and
non-nitrated FA) were added at 1 μM to the culture. After 6 h post-stimulation, cells were homogenized to preserve total mRNA, and FABP4 and CD36 mRNA were
measured by real-time qPCR and normalized to the housekeeping gene GAPDH. The expression of FABP4 (a) and CD36 (b) is represented as relative mRNA levels
(fold increase) referred to Medium group (not shown), and correspond to the mean of three independent experiments ± SD. (*) and (#) Indicate statistically
significant differences with DMSO or GW9662 treatment, respectively (Two-way ANOVA, Tukey's Multiple Comparison test */#p˂0.05, **/##p˂0.01,
***/###p˂0.001, ****/####p˂0.001). After 16 h stimulation, GW9662 effects on FABP4 upregulation by NO2-FA were examined at the protein level by Western
Blot using α-tubulin as loading control; a representative Western blot result is shown in (c), where two separate membranes from the same experiment were placed
next to each other. FABP4 protein levels were quantified by densitometry of Western blot bands from three independent experiments and normalized to Rosi. The
relative induction of FABP4 protein levels is shown in (d).
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calculations also enabled the evaluation of ligand affinities between
regioisomers of NO2-OA and NO2-CLA (not assessed in vitro), without
significant changes between isomers. These results provide further
support that nitration did not compromise FA binding to FABP4.
3.3. FABP4 nuclear import occurs independently of NO2-FA stimulation in
differentiating monocytes
NO2-FA promotion of FABP4 translocation into the nucleus was
examined in differentiating monocytes, since this translocation has
been correlated with PPARγ activation by synthetic agonists [61,62].
FABP4 translocation has been previously analyzed using artificial sys-
tems, where FABP4 was overexpressed in non-myeloid cell lines [63] or
expressed as a fusion protein with GFP, which likely interferes with the
ability of FABP4 to freely diffuse across the nuclear membrane
[59,61,62]. To avoid this interference, studies were performed by
confocal immunofluorescence microscopy using immunoaffinity-pur-
ified anti-rFABP4 antibodies for detection. FABP4 localization was first
examined in differentiating monocytes stimulated with PMA plus NO2-
FA for 10 h in order to achieve a detectable FABP4 signal (FABP4 levels
were very low in the absence of a PPARγ agonist, Fig. 2). FABP4 was
equally distributed throughout the cell, showing a nucleus to cytoplasm
ratio (N/T-N) of around 1 (Fig. 5a). Then, the effect of re-stimulation
with Rosi, NO2-FA or FAs on FABP4 localization was assessed after 30
or 60 min, as previously described for other ligands [62]. There were no
significant changes in FABP4 nuclear transport in differentiating
monocytes treated with a range of NO2-FA and Rosi concentrations
(1–10 μM) (Fig. 5b–e). In these assay conditions, total FABP4 levels in
treated and control cells were comparable, indicating that re-stimula-
tion did not induce FABP4 synthesis, which might have contributed to
the cytoplasmic signal (Fig. 5f).
In addition to FABP4 diffusion into the nucleus as a small protein,
nuclear translocation could also depend on the presence of an atypical,
and undetectable from inspection of the linear sequence, nuclear lo-
calization signal (NLS) in the three-dimensional structure of FABP4.
This is constituted by three basic residues (Lys21, Arg30, and Lys31)
[62]. The NLS is exposed in FABP4 by conformational changes induced
upon binding of an activating ligand, thus promoting a transition from
an inactive (open) to an active (closed) portal conformation. This is
characterized by the Phe57 pointing inwards and pushing outwards the
αI-loop-αII cap [53]. Because NO2-FA did not promote FABP4 nuclear
translocation in our cell model, we explored through molecular dy-
namics simulations whether NO2-FA and their corresponding native FA
precursors would facilitate NLS exposition. In agreement with previous
observations [60], the dynamics of the apo-FABP4 showed the presence
of both open and closed portal conformations, with the majority of the
population in the latter (76%, Table 3). Similarly, all FABP4:FA and
FABP4:NO2-FA complexes, showed both open and closed conformations
Fig. 4. ANS displacement from rFABP4 by NO2-FA.
rFABP4 was loaded with ANS, and FA or NO2-FA were added progressively, registering the emission spectrum of ANS after each addition. The increment in FA or
NO2-FA concentration induced a decrease in ANS fluorescence intensity. Each point corresponds to the integral of the ANS emission spectra at the indicated ligand
concentration, and the line represents the adjustment to a hyperbolic decay. ANS displacements induced by FA (open circles) or NO2-FA (filled circles) are shown for
OA/NO2-OA (a), CLA/NO2-CLA (b), AA/NO2-AA (c). Curves are representative of three independent experiments.
Table 2
Kdapp and binding free energies at 298 K for murine FABP4:FA and FABP4:NO2-FA (1:1 complexes).
Ligand In vitro (rFABP4) In silico murine FABP4
ΔGbind (kcal mol−1)
Kdapp (μM)a, b ΔGbindc (kcal mol−1) MMGBSA MMPBSA
OA 0.59 ± 0.20 −8.49 ± 0.34 −41 ± 5 −41 ± 9
9-NO2-OA 0.93 ± 0.16##e −8.22 ± 0.17 −48 ± 5 −49 ± 8
10-NO2-OA −49 ± 5 −49 ± 9
CLA 0.28 ± 0.03 −8.90 ± 0.11 −42 ± 6 −44 ± 7
9-NO2-CLA 3.03 ± 0.01∗∗∗∗/####e −7.524 ± 0.003 −49 ± 5 −49 ± 7
12-NO2-CLA −45 ± 5 −46 ± 8
AA 0.25 ± 0.02 −9.00 ± 0.08 n/ad n/ad
NO2-AA 3.02 ± 0.08∗∗∗∗
/#### −7.53 ± 0.03 n/ad n/ad
a Values correspond to the mean of three independent experiments ± SD, determined by ANS displacement experiments using each NO2-FA regioisomeric
mixture or the corresponding FA precursor.
b The (#) and (*) superscripts indicate significant differences with respect to the corresponding FA precursor or NO2-OA, respectively (One-way ANOVA, Tukey
multiple comparison test */#p˂0.05, **/##p˂0.01, ***/###p˂0.001).
c ΔGbind = -RTlnKd-app at T = 298 K.
d n/a: data not available, AA/NO2-AA complexes were not simulated.
e Corresponding to the mixture of positional isomers.
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of FABP4, but there were differences in the percentage of structures
exhibiting the closed conformation within the spectrum of conforma-
tions adopted by the protein. CLA and OA binding to FABP4 promoted a
redistribution of the native population, favoring the closed portal
conformation that exposes the NLS region (Fig. 5g and h and Table 3).
In contrast, NO2-FA binding showed dissimilar effects (Table 3).
Binding of 10-NO2-OA, but not of 9-NO2-OA, enhanced the pre-
dominance of the Phe57 closed portal conformation to a similar extent
as OA. On the other hand, 9- and 12-NO2-CLA binding to FABP4 did not
increase the predominance of the closed conformation as FA and 10-
NO2-OA did. Overall, these results indicated that NO2-FA are not better
inducers of an active/closed FABP4 conformation than their
(caption on next page)
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corresponding FA precursors.
3.4. FABP4 transduces NO2-FA signaling
Evaluation of FABP4 involvement in cell signaling by NO2-FA in
differentiating monocytes was performed using the FABP4 inhibitors
BMS and HTS, which have higher affinities for FABP4 than NO2-FA
[42,43]. Monocytes were differentiated in the presence of FABP4 in-
hibitors and afterward, cells were stimulated with NO2-FA or native FA
as control, and FABP4 and CD36 expression followed to indicate PPARγ
activation. In these assays, inhibitors did not affect basal levels of
FABP4 (Supplementary Fig. 7). BMS treatment caused a reduction in
the upregulation of FABP4 expression induced by NO2-FA and abro-
gated the CD36 expression induced by NO2-CLA (Fig. 6a and b). These
results were similarly reproduced by HTS, which strongly inhibited
FABP4 and CD36 expression by NO2-FA (Fig. 6c and d). Then, we ex-
amined the effect of FABP4 inhibitors on the NO2-FA-dependent in-
duction of HMOX1, GCLM, and HSP70 expression. We found that BMS
treatment elicited different effects on NO2-OA and NO2-CLA signaling.
NO2-OA induced significant increases in both HMOX1 and GCLM ex-
pression that were partially or completely inhibited by BMS, respec-
tively (Fig. 6e and f). In contrast, NO2-CLA caused a modest upregu-
lation of HMOX1 expression that was not inhibited by BMS treatment
(Fig. 6e). Analysis of NO2-FA activation of the HSF1 signaling showed
that NO2-OA, but not NO2-CLA, upregulated HSP70 expression, which
was significantly reduced by BMS (Fig. 6g). In contrast, when the effect
of HTS was assessed on Keap1/Nrf2 and HSF1 reporter gene expression,
a significant increase in mRNA levels of target genes was observed,
which impeded a direct comparison of gene expression between control
and treated cells. Despite this effect, normalization of gene expression
by their corresponding basal levels revealed that HTS and BMS induced
comparable inhibitory effects on NO2-FA-induced activation of Keap1/
Nrf2 (Supplementary Fig. 8).
3.5. FABP4 regulates NO2-FA modulation of cytokine expression
Cytokine expression is a feature of the inflammatory profile of
monocytes and macrophages, which is known to be modulated by NO2-
FA. Since PPARγ modulates inflammatory responses, we explored
whether activation of the PPARγ/FABP4 axis might influence cytokine
expression by differentiating monocytes. To that end, we determined
MCP1 and IL1B expression in the presence or absence of GW9662 or
BMS. NO2-OA inhibited MCP1 and IL1B expression (Fig. 7a and d),
while NO2-CLA had a marginal effect on MCP1. Moreover, considering
that GW9662 did not modify NO2-OA effects, activation of PPARγ is
likely not involved in NO2-OA modulation of cytokine expression. Al-
though PPARγ does not mitigate these anti-inflammatory effects, FABP4
does, since NO2-OA effects on MCP1 and IL1B were inhibited by FABP4
blockade (around a 87% and 44%, respectively).
4. Discussion
The pleiotropic anti-oxidant and anti-inflammatory actions of NO2-
FA have led to the present evaluation of these species as new drug
candidates designed to alleviate disorders in which physiological reg-
ulatory circuits intended to control inflammation fail [30,64]. In vivo
studies in various pre-clinical inflammatory models support this possi-
bility [65]. Despite the considerable past and current understanding of
NO2-FA actions in modulating inflammatory responses, these mostly
focused on those regulated by NF-κB and Nrf2 [27–29,66]. At present
there is limited insight into the ability of NO2-FA to activate PPARγ in
macrophages and differentiating monocytes [10,36].
We found that NO2-FA, but not native FA at similarly low con-
centrations, induced PPARγ activation in differentiating monocytes and
macrophages, reinforcing the unique impact of the electrophilic char-
acter imparted by unsaturated FA nitration. While non-physiological
concentrations of native FA activate PPARγ (around 100 μM in vitro)
[67,68], several characteristics differentiate the activity exerted by
NO2-FA from native FA. NO2-FA, are orders of magnitude more potent
activators than native FA, but are present at orders of magnitude lower
concentrations, making comparisons challenging. Importantly, by re-
acting covalently, NO2-FA have much longer occupancy times that are
determined by the rate of the elimination reaction or protein turnover
as opposed to the pharmacokinetic properties of native FAs. In addition,
while NO2-FA can compete with FA for ligand binding domain asso-
ciation, FAs will not be able to compete with adducted NO2-FA, thus
intracellular levels of NO2-FA become less relevant for initiating and
sustaining an activated state of the receptor.
Plasma levels of NO2-FA are in the very low nM range [6,9], with
net intracellular concentrations difficult to estimate as NO2-FA are
found esterified in complex lipids and covalently bound to proteins,
small thiols, and other nucleophilic intracellular molecules [69]. Thus,
the free acid fraction of NO2-FA, while in equilibrium with these other
components, is viewed to be a minor percentage [70]. Regarding in-
tracellular concentrations of free FAs, limited data has been reported
for monocytes and macrophages, with one report indicating at least 1
μmol/106 THP-1 cells [71]. In any case, in our assays 106 THP-1 cells
were treated with 2 nmoles of NO2-FA, a level orders of magnitude
lower than native FA levels, affirming that NO2-FA exert effects even
Fig. 5. NO2-FA did not increase FABP4 nuclear localization in differentiating monocytes.
(a-f) Differentiating THP-1 monocytes obtained by treatment with PMA were stimulated with 1 μM concentration of NO2-FA for 10 h and then treated with LMB
(10 ng/ml) and re-stimulated with Rosi, NO2-FA or their corresponding FA precursors in a range of concentrations (1–10 μM). In parallel, cells were re-stimulated
with DMSO (vehicle) as a control. After 30 min of re-stimulation, cells were washed and stained using affinity purified rabbit anti-rFABP4 or control antibodies, and
Alexa488 conjugated anti-rabbit IgG for development. Nuclei were stained using DAPI. Cells were observed and counted using confocal microscopy. Images were
analyzed using Image J software. Magnification (63x) of representative FABP4 distribution in cells treated with DMSO (a), CLA (b), NO2-CLA (c), or Rosi (d).
Quantification of the intracellular distribution calculated as the ratio Nuclear ID/(Total ID-Nuclear ID) (N/T-N) (e) and total integrated density (f) after 30 min of re-
stimulation. Plots showed box and whisker with bars from minimum to maximum value corresponding to the quantification of at least 30 cells per condition. Results
are representative from three independent experiments. (g) and (h) Superimposed representative structures for the most populated conformation corresponding to a
closed portal (NLS exposed), for each FA or NO2-FA, 1:1 complexes with murine FABP4 (backbone in grey) from MD simulations. Phe57 and key residues interacting
with polar heads in FA (carboxylate) and NO2-FA (carboxylate and NO2) are evidenced in stick representation. (g) OA series: OA, 9-NO2-OA and 10-NO2-OA ligands
in cyan, violet and red, respectively. (h) CLA series: CLA, 9 NO2-CLA and 12-NO2-CLA ligands in cyan, violet and red, respectively. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
Table 3
Relative weight of closed portal conformations (expressed in percentage) from
FABP4:FA and FABP4:NO2-FA complexes 1.2 μs molecular dynamics simula-
tions.








a Previously reported as 62% by Li et al. [60] using a different Amber2012
force field (ff03) for protein simulation.
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when native FA are in excess. Extents of PPARγ activation by NO2-FA
were lower in macrophages, yet there were no changes in PPARG ex-
pression levels found between differentiating monocytes and macro-
phages. The transcriptomic profile of human monocytes undergoes al-
terations during differentiation towards macrophages, which include
the induction of transcripts involved in palmitate and oleate synthesis,
as well as in fatty acid desaturation and elongation, leading to differ-
ences in the lipidomic profile [72]. In this scenario, the lower ability of
NO2-FA to activate PPARγ in macrophages may be associated with the
presence of higher-affinity and/or higher concentrations of competing
endogenous ligands in this cell type, which might render NO2-FA less
effective in PPARγ activation. In line with this hypothesis, basal PPARγ
activation, measured in terms of FABP4mRNA levels, seems to be much
greater in macrophages than in monocytes (around 16-fold,
Supplementary Fig. 9).
NO2-FA acted as partial PPARγ agonists in monocyte and
Fig. 6. Blocking FABP4 binding activity inhibits NO2-FA activation of PPARγ, Keap1/Nrf2 and HSF1 in differentiating monocytes.
(a-g) THP-1 cells were differentiated with PMA in the presence of the FABP4 inhibitor BMS (25 μM)/HTS (15 μM) or DMSO (control) for 2 h. Then, NO2-FA (1 μM) or
DMSO as control were added for 6 h. To examine NO2-FA signaling actions, total mRNA was purified and FABP4 (a and c), CD36 (b and d), HMOX1 (e), GCLM (f), or
HSP70 (g) expression, by real-time qPCR. Results are represented as relative mRNA levels (fold increase) referred to DMSO group and correspond to the mean of four
independent experiments ± SD. (*) Indicates statistically significant differences with the corresponding control (DMSO or DMSO+BMS/DMSO+HTS, Two-way
ANOVA, Tukey's Multiple Comparison test * p˂0.05, **p˂0.01, ***p˂0.001, ****p˂0.001). (#) Indicates statistically significant differences with the same treatment
without inhibitor (Two-way ANOVA, Tukey's Multiple Comparison test #p˂0.05, ##p˂0.01, ###p˂0.001, ####p˂0.001).
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macrophages, a result consistent with previous studies using biochem-
ical approaches and transfected cell lines. In all conditions and for all
reporter genes measured, the full PPARγ agonist Rosi caused a stronger
activation than NO2-OA and NO2-CLA. This behavior is likely associated
with less displacement of co-repressors and lower recruitment of co-
activators in comparison with Rosi, as previously reported for NO2-OA
[25]. Considering the potential use of NO2-OA as an anti-inflammatory
drug, this feature is not a disadvantage, as partial agonists of PPARγ
that discriminate between the beneficial actions and the adverse effects
associated with full PPARγ activation may be of clinical benefit. Thia-
zolidinedione-related increases in cardiovascular events led to both
market withdrawal and a restricted use in several countries [34]. In this
regard, understanding the differences observed in the potency and
transcriptional output of distinct NO2-FA, can help explain the mole-
cular events leading to the beneficial and/or undesirable effects
triggered by PPARγ activation. Moreover,particular NO2-FA re-
giosiomers may undergo different interactions with this nuclear re-
ceptor [22,23]).
Among NO2-FA, NO2-CLA induced a greater magnitude of PPARγ
activation, as shown by its unique upregulation of CD36 expression, a
response inhibited by GW9662. This expands our knowledge of the
biological actions of NO2-CLA in monocytes and macrophages and
presumably other cells [5,17,73,74]. Because CLA behaves as a pre-
ferential FA target for nitration at physiological conditions [5], PPARγ
activation by NO2-CLA could be biologically more relevant than that
mediated by other NO2-FA. However, whether NO2-CLA plays a role as
an endogenous PPARγ agonist and physiological regulator is still con-
troversial since NO2-CLA levels in inflamed fluids or specific anatomic
compartments of tissues from patients with acute or chronic in-
flammatory diseases are unknown. In a mouse peritonitis model, NO2-
Fig. 7. FABP4 modulates NO2-FA inhibition of cy-
tokine expression.
Differentiating THP-1 monocytes obtained by treat-
ment with PMA were stimulated with 1 μM con-
centration of Rosi, NO2-FA or their corresponding FA
precursors (a–f). In parallel, cells were incubated
with DMSO (vehicle) as a control. After 6 h stimu-
lation, cells were homogenized to obtain total mRNA
andMCP1 and IL1βmRNA levels were determined by
real-time-qPCR and normalized to the housekeeping
genes GAPDH or 18S. For BMS experiments, THP-
1 cells were differentiated with PMA in the presence
of the FABP4 inhibitor BMS (25 μM) for 2 h previous
to NO2-FA treatment (b) and (e). For GW9662 ex-
periments, differentiating monocytes were pre-
treated with GW9662 (1 μM) for 30 min previous to
NO2-FA treatment (c) and (f). The expression of
MCP1 (a–c) and IL1β (d–f) is represented as relative
mRNA levels (fold increase) referred to DMSO, and
correspond to the mean of three independent
experiments ± SD. (*) Indicates statistically sig-
nificant differences with DMSO/DMSO+BMS/
DMSO+GW9662 treatment (Two-way ANOVA,
Tukey's Multiple Comparison test *p˂0.05, **p˂0.01,
***p˂0.001, ****p˂0.001).
M. Lamas Bervejillo, et al. Redox Biology 29 (2020) 101376
12
CLA levels were ~20 nM in peritoneal lavage, indicating ~μM con-
centrations in undiluted native peritoneal fluid, as there is a limited
recovery of this chemically-reactive lipid from the peritoneal cavity
because of alternative reactions [17].
FABP4, the most highly upregulated PPARγ-reporter gene in re-
sponse to NO2-FA treatment, is a lipid carrier which binds and delivers
ligands to PPARγ [61–63,75]. FABP4 binds a series of NO2-FA with an
affinity similar or lower than that corresponding to native FA pre-
cursors, but in the intracellular milieu, this binding would depend on
the concentration of FABP4, NO2-FA as well as other competing FA li-
gands. On the other hand, the NO2-FA binding affinity for FABP4 did
not correlate with an ability to activate PPARγ, since NO2-OA showed
the highest FABP4 binding affinity (Table 2), but not the strongest
PPARγ activation activity among NO2-FA. Upon ligand binding, FABP4
undergoes structural changes, adopting the closed/active conformation
that promotes nuclear translocation and, in turn, PPARγ activation.
Thus, we compared the degree of FABP4 nuclear translocation induced
by NO2-FA and corresponding native FA precursors. In our experi-
mental conditions, FABP4 nuclear translocation was similar in differ-
entiating monocytes stimulated with NO2-FA or FA precursor. Fur-
thermore, molecular simulations showed that the closed/active
conformation of FABP4 is present in the dynamics of both FABP4:FA
and FABP4:NO2-FA complexes as in the apo-FABP4. This agrees with
the precept that in all assay conditions at least half of total FABP4 was
present in the nucleus (Fig. 5). Taking into account the unique nature of
NO2-FA-FABP4 interactions, NO2-FA seem not to play a major role in
stabilizing the active FABP4 conformation. However, NO2-FA-mediated
FABP4 translocation might be difficult to detect, considering that, as
discussed above, in the cellular milieu NO2-FA must compete with re-
latively higher concentrations of endogenous FA, and NO2-FA-FABP4
complexes are not more active in terms of nuclear translocation. Im-
portantly, the lack of correlation between the binding affinity of NO2-
FA for FABP4 and the strength of the PPARγ activation response does
not exclude the involvement of FABP4 in the mechanism of PPARγ
activation by NO2-FA. FABP4 levels might be high enough to carry high
-and low-affinity ligands, even those in low concentration such as NO2-
FA. Indeed, two different FABP4 inhibitors inhibited NO2-FA-mediated
PPARγ activation. In aggregate, this data reveals that PPARγ activation
by NO2-FA induces FABP4 upregulation and thus instigates a positive
amplification loop of this signaling pathway (Fig. 8).
Any differences in PPARγ activation by different NO2-FA and FA
could not be attributed to differences in NO2-FA-FABP4 interactions, as
nitration did not enhance FA binding to FABP4 or consequent FABP4
nuclear translocation. Therefore, it is more likely that nitration could
modify the set of interactions that determine how the lipid acyl chain is
accommodated in the ligand-binding domain (LBD) of PPARγ, thus
influencing receptor conformation and activity. The chemical features
of the ligand define the PPARγ-LBD structural changes that stabilize a
particular receptor conformation and determine the position adopted
by helix 12 and this domain's binding of co-activators and release of co-
repressors [76]. In the case of NO2-FA, the crystal structure of PPARγ
complexed with two nitrolinoleic acid (NO2-LA) regioisomers revealed
that this nitroalkene establishes specific interactions with amino acids
of the PPARγ binding pocket, which are not shared by the Rosi inter-
action network at the LBD, thus conferring partial agonism of tran-
scriptional responses [24]. These unique events include interactions
between the nitro group and Arg288 or Glu343, as well as interactions
between Phe287 and the NO2-LA backbone, required for stable binding
of NO2-LA. Furthermore, NO2-FA interactions with PPARγ-LBD are
further stabilized by the formation of a covalent bond with the redox-
sensitive Cys285 in the LBD of PPARγ [25]. Consequently, differences
in PPARγ activation by NO2-CLA, NO2-OA and NO2-AA may be related
to the set of non-covalent and covalent interactions that each ni-
troalkene establishes with the PPARγ-LBD, which in turn determine the
complex stability and the degree of conformational changes induced by
the occupancy of the ligand on the binding pocket and the downstream
recruitment/release of coactivators and corepressors.
The potential of NO2-FA to bind FABP4 and to upregulate FABP4
expression might have additional implications for tissue NO2-FA re-
sponses. To explore this, we took advantage of the ability of NO2-FA to
induce HMOX1/GCLM and HSP70 expression via Keap1/Nrf2 and
HSF1, respectively. In contrast with a modest relative activation of
PPARγ, NO2-OA was more active than NO2-CLA. Using breast cancer
cells, NO2-OA elicited greater Nrf2 and lower PPARγ transcriptional
activity responses than NO2-LA [77]. Several factors might be involved
in this differential potency for activating these signaling pathways. As
noted for PPARγ, differences in the set of non-covalent/covalent bonds
formed between NO2-FA and the target protein could affect the strength
of the signaling response. We speculate that for stress-induced tran-
scriptional responses, differences related to NO2-FA Michael addition
kinetics and equilibrium constants with thiol targets may be more im-
portant, since this will affect thiol residency time, net populations of
thiol targets and downstream propagation of the signal. These differ-
ences could also affect “signaling-productive” versus alternative NO2-
FA reactions, as this would impact the formation of adducts with thiol-
bearing pools of molecules, including glutathione and proteins not in-
volved in catalysis or the regulation of gene expression. In this context,
the greater activity showed by NO2-OA compared to NO2-CLA might be
Fig. 8. Involvement of the FABP4/PPARγ sig-
naling axis in differentiating monocyte NO2-FA
signaling.
NO2-FA behave as potential ligands of FABP4.
NO2-FA binding to FABP4 may protect them from
irrelevant adduction reactions favoring their in-
teraction with factors involved in intracellular
pathways associated with anti-oxidative and anti-
inflammatory responses (Keap1/Nrf2, HSPs/
HSF1, NF-κB). In addition, FABP4 is involved in
the activation of PPARγ triggered by NO2-FA,
which likely includes the trafficking and delivery
of these lipids to PPARγ. As a result of PPARγ
activation, FABP4 expression is upregulated,
which would operate as a positive regulation
mechanism of the FABP4/PPARγ axis.
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explained by the fact that in our assays, at the same molar concentra-
tion, NO2-OA could react more rapidly with nucleophiles than NO2-CLA
[78]. When analyzing the involvement of FABP4 in NO2-FA-induced
signaling responses, FABP4 inhibitors in turn limited the HMOX1 up-
regulation induced by NO2-OA, but not by NO2-CLA. We envision that
FABP4 could also limit NO2-FA reaction with non-productive cellular
nucleophiles such as glutathione, that in turn promotes cellular export
of NO2-FA-glutathione adducts [79]. Thus, the net effect of FABP4 se-
questration would be to promote NO2-FA reactions with more pro-
ductive targets rather than inactivation and export.
Expanding the relevance of FABP4 in regulating NO2-FA signaling,
FABP4 inhibition attenuated NO2-FA inhibition of pro-inflammatory
cytokine expression in monocytes and macrophages. There was not a
role for PPARγ in mediating these anti-inflammatory responses, sug-
gesting that NF-κB transrepression by NO2-FA-mediated PPARγ acti-
vation is less impactful than the inhibition of pro-inflammatory gene
expression via the direct adduction of NF-κB p65 by NO2-FA [10].
5. Conclusions
This work reveals that the lipid binding protein FABP4 is upregu-
lated in monocytes in response to NO2-FA mediated PPARγ activation.
It also shows that FABP4 regulates NO2-FA signaling through a cha-
perone function that probably improves the cellular transport of NO2-
FA and the downstream amplification of adaptive signaling responses.
Upon induction of FABP4 expression by inflammatory stimuli and NO2-
FA-FABP4 binding, the expression of Nrf2 and HSF-1 regulated tissue-
protective genes is enhanced and expression of pro-inflammatory cy-
tokines is inhibited. These responses to NO2-FA, all associated with
inflammatory resolution and tissue repair [80–83] are facilitated by the
chaperone activity of FABP4.
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